1 Study Coverage
    1.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
    1.2 Market by Type
        1.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Serum Biomarkers
        1.2.3 Hepatic Fibrosis Biomarkers
        1.2.4 Apoptosis Biomarkers
        1.2.5 Oxidative Stress Biomarkers
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Pharma & CRO Industry
        1.3.3 Hospitals
        1.3.4 Diagnostic Labs
        1.3.5 Academic Research Institutes
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Estimates and Forecasts 2017-2028
    2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Estimates and Forecasts 2017-2028
    2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region
        2.4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2017-2022)
        2.4.2 Global Sales NASH (Non-alcoholic Steatohepatitis) Biomarkers by Region (2023-2028)
    2.5 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region
        2.5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2017-2022)
        2.5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Manufacturers
        3.1.1 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers by Sales (2017-2022)
        3.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers in 2021
    3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Manufacturers
        3.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Manufacturers (2017-2022)
        3.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue in 2021
    3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
        4.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Historical Sales by Type (2017-2022)
        4.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Sales by Type (2023-2028)
        4.1.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
    4.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type
        4.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Historical Revenue by Type (2017-2022)
        4.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Revenue by Type (2023-2028)
        4.2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2017-2028)
    4.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type
        4.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2017-2022)
        4.3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
        5.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Historical Sales by Application (2017-2022)
        5.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Sales by Application (2023-2028)
        5.1.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
    5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application
        5.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Historical Revenue by Application (2017-2022)
        5.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Revenue by Application (2023-2028)
        5.2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2017-2028)
    5.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application
        5.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2017-2022)
        5.3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price Forecast by Application (2023-2028)
6 North America
    6.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type
        6.1.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2028)
        6.1.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2028)
    6.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Application
        6.2.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2028)
        6.2.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2028)
    6.3 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
        6.3.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2028)
        6.3.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type
        7.1.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2028)
        7.1.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2028)
    7.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Application
        7.2.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2028)
        7.2.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2028)
    7.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
        7.3.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2028)
        7.3.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type
        8.1.1 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2028)
        8.1.2 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2028)
    8.2 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Application
        8.2.1 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2028)
        8.2.2 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2028)
    8.3 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region
        8.3.1 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2017-2028)
        8.3.2 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type
        9.1.1 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2028)
        9.1.2 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2028)
    9.2 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Application
        9.2.1 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2028)
        9.2.2 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2028)
    9.3 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
        9.3.1 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2028)
        9.3.2 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type
        10.1.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2028)
        10.1.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2028)
    10.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Application
        10.2.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2028)
        10.2.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2028)
    10.3 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
        10.3.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2028)
        10.3.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 GENFIT SA
        11.1.1 GENFIT SA Corporation Information
        11.1.2 GENFIT SA Overview
        11.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 GENFIT SA Recent Developments
    11.2 Gilead Sciences, Inc. (GILD)
        11.2.1 Gilead Sciences, Inc. (GILD) Corporation Information
        11.2.2 Gilead Sciences, Inc. (GILD) Overview
        11.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Gilead Sciences, Inc. (GILD) Recent Developments
    11.3 AstraZeneca
        11.3.1 AstraZeneca Corporation Information
        11.3.2 AstraZeneca Overview
        11.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 AstraZeneca Recent Developments
    11.4 Novartis AG
        11.4.1 Novartis AG Corporation Information
        11.4.2 Novartis AG Overview
        11.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Novartis AG Recent Developments
    11.5 Bristol-Myers Squibb Company
        11.5.1 Bristol-Myers Squibb Company Corporation Information
        11.5.2 Bristol-Myers Squibb Company Overview
        11.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Bristol-Myers Squibb Company Recent Developments
    11.6 Allergan Plc
        11.6.1 Allergan Plc Corporation Information
        11.6.2 Allergan Plc Overview
        11.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Allergan Plc Recent Developments
    11.7 Novo Nordisk A/S
        11.7.1 Novo Nordisk A/S Corporation Information
        11.7.2 Novo Nordisk A/S Overview
        11.7.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Novo Nordisk A/S Recent Developments
    11.8 Boehringer Ingelheim
        11.8.1 Boehringer Ingelheim Corporation Information
        11.8.2 Boehringer Ingelheim Overview
        11.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Boehringer Ingelheim Recent Developments
    11.9 Pfizer Inc
        11.9.1 Pfizer Inc Corporation Information
        11.9.2 Pfizer Inc Overview
        11.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Pfizer Inc Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Chain Analysis
    12.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Mode & Process
    12.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales and Marketing
        12.4.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Channels
        12.4.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors
    12.5 NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Trends
    13.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers
    13.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Challenges
    13.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints
14 Key Findings in The Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Serum Biomarkers
    Table 3. Major Manufacturers of Hepatic Fibrosis Biomarkers
    Table 4. Major Manufacturers of Apoptosis Biomarkers
    Table 5. Major Manufacturers of Oxidative Stress Biomarkers
    Table 6. Major Manufacturers of Others
    Table 7. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 9. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2017-2022) & (K Units)
    Table 10. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2017-2022)
    Table 11. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2023-2028) & (K Units)
    Table 12. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2023-2028)
    Table 13. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2017-2022) & (US$ Million)
    Table 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2017-2022)
    Table 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2023-2028) & (US$ Million)
    Table 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2023-2028)
    Table 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Manufacturers (2017-2022) & (K Units)
    Table 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Manufacturers (2017-2022)
    Table 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 20. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Manufacturers (2017-2022)
    Table 21. NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Manufacturers (2017-2022) &(USD/Unit)
    Table 22. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 23. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NASH (Non-alcoholic Steatohepatitis) Biomarkers as of 2021)
    Table 24. NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base Distribution and Headquarters
    Table 25. Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Offered
    Table 26. Date of Manufacturers Enter into NASH (Non-alcoholic Steatohepatitis) Biomarkers Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
    Table 29. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
    Table 30. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Type (2017-2022)
    Table 31. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Type (2023-2028)
    Table 32. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2022) & (US$ Million)
    Table 33. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2023-2028) & (US$ Million)
    Table 34. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Type (2017-2022)
    Table 35. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Type (2023-2028)
    Table 36. NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2017-2022) & (USD/Unit)
    Table 37. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price Forecast by Type (2023-2028) & (USD/Unit)
    Table 38. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
    Table 39. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
    Table 40. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Application (2017-2022)
    Table 41. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Application (2023-2028)
    Table 42. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2022) & (US$ Million)
    Table 43. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2023-2028) & (US$ Million)
    Table 44. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Application (2017-2022)
    Table 45. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Application (2023-2028)
    Table 46. NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2017-2022) & (USD/Unit)
    Table 47. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price Forecast by Application (2023-2028) & (USD/Unit)
    Table 48. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
    Table 49. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
    Table 50. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2022) & (US$ Million)
    Table 51. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2023-2028) & (US$ Million)
    Table 52. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
    Table 53. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
    Table 54. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2022) & (US$ Million)
    Table 55. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2023-2028) & (US$ Million)
    Table 56. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2022) & (K Units)
    Table 57. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2023-2028) & (K Units)
    Table 58. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2022) & (US$ Million)
    Table 59. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2023-2028) & (US$ Million)
    Table 60. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
    Table 61. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
    Table 62. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2022) & (US$ Million)
    Table 63. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2023-2028) & (US$ Million)
    Table 64. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
    Table 65. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
    Table 66. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2022) & (US$ Million)
    Table 67. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2023-2028) & (US$ Million)
    Table 68. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2022) & (K Units)
    Table 69. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2023-2028) & (K Units)
    Table 70. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2022) & (US$ Million)
    Table 71. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2023-2028) & (US$ Million)
    Table 72. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
    Table 73. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
    Table 74. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2022) & (US$ Million)
    Table 75. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2023-2028) & (US$ Million)
    Table 76. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
    Table 77. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
    Table 78. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2022) & (US$ Million)
    Table 79. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2023-2028) & (US$ Million)
    Table 80. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2017-2022) & (K Units)
    Table 81. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2023-2028) & (K Units)
    Table 82. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2017-2022) & (US$ Million)
    Table 83. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2023-2028) & (US$ Million)
    Table 84. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
    Table 85. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
    Table 86. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2022) & (US$ Million)
    Table 87. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2023-2028) & (US$ Million)
    Table 88. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
    Table 89. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
    Table 90. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2022) & (US$ Million)
    Table 91. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2023-2028) & (US$ Million)
    Table 92. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2022) & (K Units)
    Table 93. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2023-2028) & (K Units)
    Table 94. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2022) & (US$ Million)
    Table 95. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2023-2028) & (US$ Million)
    Table 96. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
    Table 97. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
    Table 98. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2022) & (US$ Million)
    Table 99. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2023-2028) & (US$ Million)
    Table 100. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
    Table 101. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
    Table 102. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2022) & (US$ Million)
    Table 103. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2023-2028) & (US$ Million)
    Table 104. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2022) & (K Units)
    Table 105. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2023-2028) & (K Units)
    Table 106. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2022) & (US$ Million)
    Table 107. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2023-2028) & (US$ Million)
    Table 108. GENFIT SA Corporation Information
    Table 109. GENFIT SA Description and Major Businesses
    Table 110. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 111. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
    Table 112. GENFIT SA Recent Developments
    Table 113. Gilead Sciences, Inc. (GILD) Corporation Information
    Table 114. Gilead Sciences, Inc. (GILD) Description and Major Businesses
    Table 115. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 116. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
    Table 117. Gilead Sciences, Inc. (GILD) Recent Developments
    Table 118. AstraZeneca Corporation Information
    Table 119. AstraZeneca Description and Major Businesses
    Table 120. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 121. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
    Table 122. AstraZeneca Recent Developments
    Table 123. Novartis AG Corporation Information
    Table 124. Novartis AG Description and Major Businesses
    Table 125. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 126. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
    Table 127. Novartis AG Recent Developments
    Table 128. Bristol-Myers Squibb Company Corporation Information
    Table 129. Bristol-Myers Squibb Company Description and Major Businesses
    Table 130. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 131. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
    Table 132. Bristol-Myers Squibb Company Recent Developments
    Table 133. Allergan Plc Corporation Information
    Table 134. Allergan Plc Description and Major Businesses
    Table 135. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 136. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
    Table 137. Allergan Plc Recent Developments
    Table 138. Novo Nordisk A/S Corporation Information
    Table 139. Novo Nordisk A/S Description and Major Businesses
    Table 140. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 141. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
    Table 142. Novo Nordisk A/S Recent Developments
    Table 143. Boehringer Ingelheim Corporation Information
    Table 144. Boehringer Ingelheim Description and Major Businesses
    Table 145. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 146. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
    Table 147. Boehringer Ingelheim Recent Developments
    Table 148. Pfizer Inc Corporation Information
    Table 149. Pfizer Inc Description and Major Businesses
    Table 150. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 151. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
    Table 152. Pfizer Inc Recent Developments
    Table 153. Key Raw Materials Lists
    Table 154. Raw Materials Key Suppliers Lists
    Table 155. NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors List
    Table 156. NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers List
    Table 157. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Trends
    Table 158. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers
    Table 159. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Challenges
    Table 160. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints
    Table 161. Research Programs/Design for This Report
    Table 162. Key Data Information from Secondary Sources
    Table 163. Key Data Information from Primary Sources
List of Figures
    Figure 1. NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Picture
    Figure 3. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Type in 2021 & 2028
    Figure 3. Serum Biomarkers Product Picture
    Figure 4. Hepatic Fibrosis Biomarkers Product Picture
    Figure 5. Apoptosis Biomarkers Product Picture
    Figure 6. Oxidative Stress Biomarkers Product Picture
    Figure 7. Others Product Picture
    Figure 8. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Application in 2021 & 2028
    Figure 9. Pharma & CRO Industry
    Figure 10. Hospitals
    Figure 11. Diagnostic Labs
    Figure 12. Academic Research Institutes
    Figure 13. NASH (Non-alcoholic Steatohepatitis) Biomarkers Report Years Considered
    Figure 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2017-2028 (K Units)
    Figure 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2017-2028 (US$ Million)
    Figure 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2017-2022)
    Figure 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2023-2028)
    Figure 20. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales YoY (2017-2028) & (K Units)
    Figure 21. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales YoY (2017-2028) & (K Units)
    Figure 23. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales YoY (2017-2028) & (K Units)
    Figure 25. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales YoY (2017-2028) & (K Units)
    Figure 27. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales YoY (2017-2028) & (K Units)
    Figure 29. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue YoY (2017-2028) & (US$ Million)
    Figure 30. The NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 31. The Top 5 and 10 Largest Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers in the World: Market Share by NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue in 2021
    Figure 32. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 33. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
    Figure 34. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2017-2028)
    Figure 35. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
    Figure 36. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2017-2028)
    Figure 37. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
    Figure 38. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2017-2028)
    Figure 39. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
    Figure 40. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2017-2028)
    Figure 41. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Country (2017-2028)
    Figure 42. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Country (2017-2028)
    Figure 43. U.S. NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 44. Canada NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 45. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
    Figure 46. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2017-2028)
    Figure 47. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
    Figure 48. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2017-2028)
    Figure 49. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Country (2017-2028)
    Figure 50. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Country (2017-2028)
    Figure 51. Germany NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 52. France NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 53. U.K. NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 54. Italy NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 55. Russia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 56. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
    Figure 57. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2017-2028)
    Figure 58. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
    Figure 59. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2017-2028)
    Figure 60. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Region (2017-2028)
    Figure 61. Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Region (2017-2028)
    Figure 62. China NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 63. Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 64. South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 65. India NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 66. Australia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 67. Taiwan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 68. Indonesia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 69. Thailand NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 70. Malaysia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 71. Philippines NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 72. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
    Figure 73. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2017-2028)
    Figure 74. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
    Figure 75. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2017-2028)
    Figure 76. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Country (2017-2028)
    Figure 77. Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Country (2017-2028)
    Figure 78. Mexico NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 79. Brazil NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 80. Argentina NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 81. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
    Figure 82. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2017-2028)
    Figure 83. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
    Figure 84. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2017-2028)
    Figure 85. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Share by Country (2017-2028)
    Figure 86. Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Share by Country (2017-2028)
    Figure 87. Turkey NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 88. Saudi Arabia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 89. UAE NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (US$ Million)
    Figure 90. NASH (Non-alcoholic Steatohepatitis) Biomarkers Value Chain
    Figure 91. NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Process
    Figure 92. Channels of Distribution
    Figure 93. Distributors Profiles
    Figure 94. Bottom-up and Top-down Approaches for This Report
    Figure 95. Data Triangulation
    Figure 96. Key Executives Interviewed